Business Insights

Latest Evidence and Effects of Vitamin D3 (cholecalciferol)-Drug Interactions

October 15, 2022

Latest Evidence
Because vitamin D receptors are present in most cells in the
body, its active form has potent effects on the growth and
differentiation of many types of cells, meaning that vitamin
D

Spotlight

Archimica

Archimica is a privately held pharmaceutical fine chemical company that combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years. We are particularly focused on custom synthesis of high-tech building blocks, intermediates and APIs in close cooperation with our clients.

OTHER WHITEPAPERS
news image

Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | January 24, 2022

Semantics is the process of assigning meaning to words and is a vital step in making unstructured scientific content machine readable, contextualizing otherwise unstructured information. It unlocks a host of benefits to search and analytics which are outlined below in the context of use cases relevant to drug discovery.

Read More
news image

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More
news image

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More
news image

Using High Throughput SPR to Explore the Full Kinetic and Epitope Diversity of Large Antibody Libraries

whitePaper | February 24, 2023

A new way of thinking and working has evolved for the discovery of therapeutic antibodies. Until recently, large numbers of antibodies were generated, only for a relatively small fraction to be sampled and engineered for further lead generation.

Read More

Spotlight

Archimica

Archimica is a privately held pharmaceutical fine chemical company that combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years. We are particularly focused on custom synthesis of high-tech building blocks, intermediates and APIs in close cooperation with our clients.

Events